- Home
- DMAC vs AGAE Comparison
DMAC vs AGAE Comparison
Compare DMAC & AGAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- AGAE
- Stock Information
- Founded
- DMAC 2000
- AGAE 2017
- Country
- DMAC United States
- AGAE United States
- Employees
- DMAC N/A
- AGAE N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- AGAE Cable & Other Pay Television Services
- Sector
- DMAC Health Care
- AGAE Telecommunications
- Exchange
- DMAC Nasdaq
- AGAE Nasdaq
- Market Cap
- DMAC 178.0M
- AGAE 144.7M
- IPO Year
- DMAC N/A
- AGAE N/A
- Fundamental
- Price
- DMAC $3.63
- AGAE $3.03
- Analyst Decision
- DMAC Strong Buy
- AGAE
- Analyst Count
- DMAC 2
- AGAE 0
- Target Price
- DMAC $8.00
- AGAE N/A
- AVG Volume (30 Days)
- DMAC 110.0K
- AGAE 424.2K
- Earning Date
- DMAC 08-06-2025
- AGAE 06-27-2025
- Dividend Yield
- DMAC N/A
- AGAE N/A
- EPS Growth
- DMAC N/A
- AGAE N/A
- EPS
- DMAC N/A
- AGAE N/A
- Revenue
- DMAC N/A
- AGAE $9,079,172.00
- Revenue This Year
- DMAC N/A
- AGAE N/A
- Revenue Next Year
- DMAC N/A
- AGAE N/A
- P/E Ratio
- DMAC N/A
- AGAE N/A
- Revenue Growth
- DMAC N/A
- AGAE 18.60
- 52 Week Low
- DMAC $2.14
- AGAE $0.70
- 52 Week High
- DMAC $6.82
- AGAE $3.79
- Technical
- Relative Strength Index (RSI)
- DMAC 46.56
- AGAE 56.56
- Support Level
- DMAC $4.02
- AGAE $2.70
- Resistance Level
- DMAC $4.17
- AGAE $3.74
- Average True Range (ATR)
- DMAC 0.25
- AGAE 0.49
- MACD
- DMAC -0.04
- AGAE -0.07
- Stochastic Oscillator
- DMAC 37.89
- AGAE 47.01
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.